Video

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the treatment of patients with renal cell carcinoma (RCC).

Motzer highlights the results of a phase Ib trial that showed promising activity for ipilimumab in combination with nivolumab. The study looked at different dose levels with the regimen and identified a specific dosage and combination that was both well tolerated and effective: nivolumab at 3 mg/kg with ipilimumab at 1 mg/kg. When the researchers tested a higher dose of ipilimumab, they saw increased toxicity.

These findings led to a large randomized phase III trial, CheckMate-214, which compared sunitinib (Sutent) with nivolumab and ipilimumab in the first-line setting. That trial has now completed accrual, and according to Motzer, results are expected in 2017 or early 2018.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.